Shanghai Labway Clinical Laboratory Co Ltd (SHE:301060) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai Labway Clinical Laboratory Co Ltd (301060)
Shanghai Labway Clinical Laboratory Co Ltd (SHE:301060) has a market capitalization of $700.95 Million (CN¥4.79 Billion) as of August 15, 2026. Listed on the SHE stock exchange, this China-based company holds position #10599 globally and #2875 in its home market, demonstrating a 33.48% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Labway Clinical Laboratory Co Ltd's stock price CN¥11.96 by its total outstanding shares 400517000 (400.52 Million). See Shanghai Labway Clinical Laboratory Co L net asset quality index to understand what proportion of total assets are financed by equity.
Shanghai Labway Clinical Laboratory Co Ltd Market Cap History: 2021 to 2026
Shanghai Labway Clinical Laboratory Co Ltd's market capitalization history from 2021 to 2026. Data shows change from $1.98 Billion to $700.95 Million (-7.77% CAGR). Also see Shanghai Labway Clinical Laboratory Co L total assets for a full breakdown of the balance sheet.
Shanghai Labway Clinical Laboratory Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Labway Clinical Laboratory Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Shanghai Labway Clinical Laboratory Co L stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.37x
Shanghai Labway Clinical Laboratory Co Ltd's market cap is 0.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.98 Billion | $1.78 Billion | $203.84 Million | 1.12x | 9.73x |
| 2022 | $1.13 Billion | $4.20 Billion | $617.32 Million | 0.27x | 1.83x |
| 2023 | $778.90 Million | $1.67 Billion | -$141.59 Million | 0.47x | N/A |
| 2024 | $533.92 Million | $1.74 Billion | -$109.44 Million | 0.31x | N/A |
| 2025 | $542.13 Million | $1.45 Billion | -$30.75 Million | 0.37x | N/A |
Competitor Companies of 301060 by Market Capitalization
Companies near Shanghai Labway Clinical Laboratory Co Ltd in the global market cap rankings as of August 15, 2026. Also see Shanghai Labway Clinical Laboratory Co L cash conversion from operations for how efficiently the company converts equity into cash flow.
Key companies related to Shanghai Labway Clinical Laboratory Co Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #85 globally with a market cap of $223.88 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #165 globally with a market cap of $144.02 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #457 globally with a market cap of $58.75 Billion USD ( CN¥401.49 Billion CNY).
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #623 globally with a market cap of $43.83 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #85 | Thermo Fisher Scientific Inc | NYSE:TMO | $223.88 Billion | $595.89 |
| #165 | Danaher Corporation | NYSE:DHR | $144.02 Billion | $203.89 |
| #457 | WuXi AppTec Co Ltd | SHG:603259 | $58.75 Billion | CN¥162.33 |
| #623 | IDEXX Laboratories Inc | NASDAQ:IDXX | $43.83 Billion | $566.93 |
Shanghai Labway Clinical Laboratory Co Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Shanghai Labway Clinical Laboratory Co Ltd's market cap moved from $1.98 Billion to $ 700.95 Million, with a yearly change of -7.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥700.95 Million | +29.30% |
| 2025 | CN¥542.13 Million | +1.54% |
| 2024 | CN¥533.92 Million | -31.45% |
| 2023 | CN¥778.90 Million | -30.98% |
| 2022 | CN¥1.13 Billion | -43.10% |
| 2021 | CN¥1.98 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 14th, 2026 the market cap of Shanghai Labway Clinical Laboratory Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $700.95 Million USD |
| MoneyControl | $700.95 Million USD |
| MarketWatch | $700.95 Million USD |
| marketcap.company | $700.95 Million USD |
| Reuters | $700.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Labway Clinical Laboratory Co Ltd
Shanghai Labway Clinical Laboratory Co., Ltd. engages in the sale of in-vitro diagnostic products in China. The company distributes in-vitro diagnostic instruments, reagents, and related accessories and consumables. It also provides third-party medical testing, pathological diagnosis services, precision medicine, CRO, and sample bank laboratory services; scientific research technology and testing… Read more